Evidence map›Paper›PMID 37435418›Full record

ArticleJournal of hematology2023

Hyperammonemic Encephalopathy: A Rare Presentation of Relapsed Multiple Myeloma.

Sasmith R Menakuru, Mona Atta, Nischala Ammannagari, Mohamad Younes

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sasmith R MenakuruDepartment of Internal Medicine, Indiana University School of Medicine, Muncie, IN, USA.
Mona AttaDepartment of Internal Medicine, Indiana University School of Medicine, Muncie, IN, USA.
Nischala AmmannagariHematology Oncology, New York Oncology Hematology, Albany, NY, USA.
Mohamad YounesHematology Oncology, New York Oncology Hematology, Albany, NY, USA.
Ball State University · USNew York Oncology Hematology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperammonemia is a rare cause of encephalopathy in multiple myeloma in the absence of hepatic involvement. This is the only reported case of a 74-year-old man who presented with multiple myeloma and achieved complete remission but developed hyperammonemia afterward. He was aggressively treated with a combination of chemotherapy and immunotherapy, with a resolution of his encephalopathy; however, within one month, he relapsed with encephalopathy. He ultimately decided to pursue comfort-care measures. The authors conclude that hyperammonemia in multiple myeloma is a rare but important differential in patients with encephalopathy of unknown causes. Aggressive treatment is of the utmost importance due to the high mortality associated with the condition.

Indexed as

EncephalopathyHyperammonemiaMultiple myelomaTreatment

Identifiers

PMID37435418
PMCPMC10332859
OpenAlexW4368617821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.